Trial Profile
A Single-center, Open-label Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 and the Effect of Single- and Multiple-dose ACT-541468 on the Pharmacokinetics of Midazolam and Its Metabolite 1-Hydroxymidazolam in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary) ; Midazolam (Primary)
- Indications Insomnia; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 04 Oct 2018 Results from two interaction studies (CTP: 280702 and CTP: 260030 ) published in the European Journal of Clinical Pharmacology.
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 28 Feb 2017 Status changed to completed.